Publications by authors named "Ryan D Gentzler"

Claim this Profile
B
Brief Report: Central Nervous System Metastases After Chemoradiation Followed by Durvalumab for Unresectable Locally Advanced Nonsmall Cell Lung Cancer.
John Sharp, Philip Young, Songzhu Zhao, Lai Wei, Sandip H Patel, Ryan D Gentzler

Clin Lung Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase II study of GT103 in combination with pembrolizumab in refractory, metastatic non-small cell lung cancer.
Hirva Mamdani, Ryan D Gentzler, Lin Gu, Alberto A Chiappori, Frank D Weinberg

Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Outcomes of Tarlatamab in Small Cell Lung Cancer, Including Patients With Untreated Brain Metastases.
Fabian J Bolte, Sean C Dougherty, Abigail O Danos, Alia C Lynch, Yaroslav Shvorak, Ryan D Gentzler

Clin Lung Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plain language summary of MARIPOSA-2: amivantamab-chemotherapy either with or without lazertinib for treatment of non-small-cell lung cancer.
Antonio Passaro, Alexis B Cortot, Ryan D Gentzler, Karen L Reckamp, Sujay Shah

Future Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Successful Treatment of Innumerable Untreated Brain Metastases With Trastuzumab Deruxtecan in Chemotherapy-Naïve HER2-Mutated Non-Small-Cell Lung Cancer.
Sara Young, Sean C Dougherty, Angela M DeRidder, Camilo E Fadul, Ryan D Gentzler

Case Rep Oncol Med· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Osimertinib for uncommon EGFR mutations: herding UNICORNs in a field of horses.
Sean C Dougherty, Ryan D Gentzler

Transl Cancer Res· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First Report of Response to Tarlatamab in a Patient With DLL3-Positive Pulmonary Carcinoid: Case Report.
Alissa J Cooper, Natasha Rekhtman, Marina K Baine, Marie C Thomas, Alia C Lynch, Ryan D Gentzler

JTO Clin Res Rep· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study.
Joel W Neal, Armando Santoro, Maria Gonzalez-Cao, Farah Louise Lim, Bruno Fang, Ryan D Gentzler

JTO Clin Res Rep· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dynamic Changes in Circulating Tumor Fraction as a Predictor of Real-World Clinical Outcomes in Solid Tumor Malignancy Patients Treated with Immunotherapy.
Ryan D Gentzler, John Guittar, Akash Mitra, Wade T Iams, Terri Driessen

Oncol Ther· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spatial colocalization and combined survival benefit of natural killer and CD8 T cells despite profound MHC class I loss in non-small cell lung cancer.
Remziye E Wessel, Nardin Ageeb, Joseph M Obeid, Ileana S Mauldin, Kate A Goundry, Ryan D Gentzler

J Immunother Cancer· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Implications for practice: phase II/III trial of carboplatin and irinotecan for elderly patients with extensive-stage small-cell lung cancer in Japan.
Shipra Maheshwari, Ryan D Gentzler

J Thorac Dis· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spatial colocalization and combined survival benefit of natural killer and CD8 T cells despite profound MHC class I loss in non-small cell lung cancer.
Remziye E Wessel, Nardin Ageeb, Joseph M Obeid, Ileana Mauldin, Kate A Goundry, Ryan D Gentzler

bioRxiv· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I/II Trial of Carboplatin, Nab-paclitaxel, and Pembrolizumab for Advanced Non-Small Cell Lung Cancer: Hoosier Cancer Research Network LUN13-175.
Ryan D Gentzler, Nisha A Mohindra, Shadia I Jalal, Karen L Reckamp, Richard D Hall

Oncologist· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Opioid Use on Duration of Therapy and Overall Survival for Patients with Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors.
Philip Young, Omar Elghawy, Joseph Mock, Emmett Wynter, Ryan D Gentzler

Curr Oncol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399.
Ryan D Gentzler, Liza C Villaruz, John C Rhee, Bethany Horton, Joseph Mock

Oncologist· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
mHealth for Medication and Side Effect Monitoring: Patients' Attitudes Toward Smart Devices for Managing Oral Chemotherapy During Lung Cancer Treatment.
Anna N Baglione, Sarah Tolman, Chloe Dapaah, Danielle Johnson, Kristen J Wells, Ryan D Gentzler

Int Conf Pervasive Comput Technol Healthc· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relevance of the Updated Recursive Partitioning Analysis (U-RPA) Classification in the Contemporary Care of Patients with Brain Metastases.
Camilo E Fadul, Guneet Sarai, Joseph A Bovi, Alissa A Thomas, Wendy Novicoff, Ryan D Gentzler

Cancers (Basel)· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune-Related Adverse Events in Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibition in Combination With Chemotherapy: A Brief Report.
Lindsey B Shantzer, Sean C Dougherty, Fabian Bolte, John W Melson, Daniel R Reed, Ryan D Gentzler

Clin Lung Cancer· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase II Trial of Atezolizumab Plus Carboplatin Plus Pemetrexed Plus Bevacizumab in the Treatment of Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer: Big Ten Cancer Research Consortium (BTCRC)- LUN 17-139.
Fatemeh Ardeshir-Larijani, Sandra K Althouse, Ticiana Leal, Lawrence Eric Feldman, Taher Abu Hejleh, Ryan D Gentzler

Clin Lung Cancer· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Replicative Instability Drives Cancer Progression.
Benjamin B Morris, Jason P Smith, Qi Zhang, Zhijie Jiang, Oliver A Hampton, Ryan D Gentzler

Biomolecules· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of sarcopenia with survival in advanced NSCLC patients receiving concurrent immunotherapy and chemotherapy.
Fabian J Bolte, Sloane McTavish, Nathan Wakefield, Lindsey Shantzer, Caroline Hubbard, Ryan D Gentzler

Front Oncol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.
Jonathan D Schoenfeld, Anita Giobbie-Hurder, Srinika Ranasinghe, Katrina Z Kao, Ana Lako, Ryan D Gentzler

Lancet Oncol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bayesian Design for Identifying Cohort-Specific Optimal Dose Combinations Based on Multiple Endpoints: Application to a Phase I Trial in Non-Small Cell Lung Cancer.
Bethany Jablonski Horton, Nolan A Wages, Ryan D Gentzler

Int J Environ Res Public Health· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer.
Arta M Monjazeb, Anita Giobbie-Hurder, Ana Lako, Emily M Thrash, Ryan C Brennick, Ryan D Gentzler

Clin Cancer Res· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with Exon 20 Insertion Mutations from a Phase I/II Trial.
Gregory J Riely, Joel W Neal, D Ross Camidge, Alexander I Spira, Zofia Piotrowska, Ryan D Gentzler

Cancer Discov· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis